FDA Grants Priority Review for Ruxolitinib (Jakafi) for Acute Graft-Versus-Host Disease

FDA Grants Priority Review for Ruxolitinib (Jakafi) for Acute Graft-Versus-Host Disease

Submitted by admin on October 25, 2018 - 9:52am
Source: 
CP Wire
News Tags: 
FDA
Incyte
Novartis
Jakavi
Jakafi
graft vs host disease
Headline: 
FDA Grants Priority Review for Ruxolitinib (Jakafi) for Acute Graft-Versus-Host Disease
snippet: 
  • The FDA previously granted ruxolitinib Breakthrough Therapy Designation for the treatment of acute GVHD
  • Jakafi is marketed by Incyte in the United States and by Novartis as Jakavi (ruxolitinib) outside the United States
  • Jakafi is also indicated for treatment of people with intermediate or high-risk myelofibrosis

Do Not Allow Advertisers to Use My Personal information